Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,520.00
(
-1.88%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.06
(
5.35%
)
Bitcoin
66,012.59
(
-4.05%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

caravon

Send PM Follow Ignore
Followers 12
Posts 1058
Boards Moderated 0
Alias Born 02/21/2007

caravon

Re: caravon post# 149707

Monday, 10/01/2012 3:12:48 PM

Monday, October 01, 2012 3:12:48 PM

Post# of 257295
Giving one more look at the Tivantinib PhII trial data, it becomes quite obvious to me that the c-MET+ biomarker overwhelmingly superior to all other biomarkers (histology, KRAS, and EGFR) in predicting Tivantinib benefits in treating NSCLC pts even in specific subgroups such as KRAS and EGFR wild/mutant pts.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today